News Breaks |
|
|
| February 12, 2013 |
| 06:57 EDT |  | VNDA, NVS | Vanda Pharmaceuticals reports Q4 EPS (23c), consensus (22c)
Reports Q4 revenue $7.9M, consensus $8.6M. Q4 revenues included $1.2M in Fanapt royalties received from Novartis (NVS). |
|
|
News For VNDA;NVS From The Last 14 Days Check below for free stories on VNDA;NVS the last two weeks. |
|
|
| May 22, 2013 |
| 09:59 EDT |  | VNDA | Vanda Pharmaceuticals management to meet with Lazard Capital
 Subscribe for More Information |
|
| May 21, 2013 |
| 07:44 EDT | | NVS | Sachs Associates to host a forum
Subscribe for More Information |
|
| 07:24 EDT | | NVS | Global Health Care to host a conference
Subscribe for More Information |
|
| May 20, 2013 |
| 07:29 EDT | | NVS | Deutsche Bank to host a conference
dbAccess Asia Conference 2013 is being held in Singapore on May 20-22. |
|
| May 17, 2013 |
| 16:20 EDT |  | NVS | Novartis drug Afinitor extended time without disease progression in women
Subscribe for More Information |
|
| 11:39 EDT |  | VNDA | High option volume stocks: GNK VNDA BYI ARUN BYI ILMN
Subscribe for More Information |
|
| 07:37 EDT |  | VNDA | Vanda Pharmaceuticals price target raised to $17 from $11 at Lazard Capital
Subscribe for More Information |
|
| May 16, 2013 |
| 08:11 EDT | | NVS | Novartis says no intention of pursuing Actavis, Bloomberg reports
Subscribe for More Information |
|
| May 15, 2013 |
| 19:37 EDT |  | NVS | Novartis weighing Actavis bid, WSJ reports
Subscribe for More Information |
|
| 18:17 EDT | | NVS | Novartis weighs possible bid for Actavis, DJ reports
Subscribe for More Information |
| |
| May 10, 2013 |
| 05:42 EDT | | NVS | Novartis drug Ilaris approved by FDA
Subscribe for More Information |
|
| May 9, 2013 |
| 06:59 EDT | | VNDA | Vanda Pharmaceuticals sees FY13 operating expense $57M-$62M
Subscribe for More Information |
|
| 06:57 EDT | | VNDA | Vanda Pharmaceuticals reports Q1 EPS (15c), consensus (25c)
Subscribe for More Information |
|
|
|
|
|
